MiMedx Group, Inc. filed a Form 8-K on October 28, 2026, reporting third-quarter 2026 operating and financial results, including a conference call presentation and updated investor materials, filed under NASDAQ:MDXG.

Key Highlights

  • Net sales of $62 million for the three months ended September 30, 2026, compared to $114 million for the same period in 2025, a decrease of 45%, according to the filing.
  • Surgical product sales increased 9% year-over-year, led by sales of AMNIOFIX, AMNIOEFFECT, and HELIOGEN, the company disclosed.
  • Wound Care sales declined 71% year-over-year, despite continued sequential growth of sales to Wound Care Centers, per the filing.
  • Wound Care Center unit volume grew 7% sequentially in the third quarter, according to the company's statement.
  • Surgical franchise delivered mid-teens volume growth and now represents "nearly two-thirds" of net sales, the company reported.
  • Favorable federal court ruling in the AXIOFILL regulatory classification matter was obtained during the quarter, per the filing.
  • Patent license agreement announced on October 28, 2026, which the company described as "underscoring strength of IP portfolio."

MiMedx Q3 2026: Surgical Growth Offsets Steep Wound Care Decline

MiMedx Group, Inc. (NASDAQ:MDXG), headquartered in Marietta, Georgia, reported third-quarter 2026 results via an 8-K filing dated October 28, 2026. According to the filing, net sales for the three months ended September 30, 2026 totaled $62 million, down from $114 million in the year-earlier period, a decline of 45%. The company attributed the overall decrease primarily to a 71% year-over-year drop in Wound Care sales, which was only partially offset by a 9% increase in Surgical product sales.

Chief Executive Officer Joseph H. Capper stated in the filing that the results reflect progress in "reshaping MIMEDX into a Surgical-led company with a leaner cost structure that returned us to positive Adjusted EBITDA." He noted that Surgical volume growth was delivered "against a strong prior-year comparison and softer U.S. surgical procedure volumes," and that "a few discrete items dampened reported Surgical sales growth of 9% in the quarter." Mr. Capper also noted that the Wound Care market is "working through a sluggish reset," and that MIMEDX Wound Care Center unit volume grew 7% sequentially during the quarter.

The filing also disclosed that MiMedx is working with the FTC to obtain HSR clearance for its pending acquisition of Sanara MedTech. Mr. Capper stated that the company's "conviction in both the strategic rationale and the financial merits of this transaction remains strong." A conference call and webcast was scheduled for October 28, 2026, at 4:30 PM Eastern Daylight Time to discuss the results. The 8-K includes three exhibits: the earnings press release, the earnings call presentation, and an updated investor presentation, all dated October 28, 2026. The filing contains forward-looking statements, which the company cautions are subject to risks and uncertainties as described in its annual and quarterly reports filed with the SEC.

What Was Disclosed

MiMedx filed an 8-K on October 28, 2026, under Items 2.02 and 7.01, disclosing Q3 2026 financial results showing net sales of $62 million, a 45% year-over-year decline, along with materials for an earnings call and an updated investor presentation.